Phase 1 study for people with Lung Cancer

Recruiting Phase 1

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 1
Sponsor TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Registry number NCT06343402
Started 22 May 2024 Today 16 October 2026 Estimated completion 1 April 2031

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Kinghorn Cancer Centre Darlinghurst NSW Recruiting
Flinders Medical Centre Bedford Park SA Recruiting
The Queen Elizabeth Hospital Woodville South SA Recruiting
Peninsula & South Eastern Hematology and Oncology Group (PAS) Frankston VIC Recruiting
Peter MacCallum Cancer Centre Melbourne VIC Recruiting
Linear Clinical Research Nedlands WA Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 350

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Histologically documented locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS G12C mutation

* Measurable disease by RECIST v1.1

* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1

Exclusion Criteria:

* Patients with malignancy within the last 2 years as specified in the protocol

* Patients with untreated or unstable brain metastases

* Patients with known hypersensitivity to BBO-8520 or its excipients

* For Cohorts 1b and 2b:

* Patients with a known hypersensitivity to pembrolizumab or its excipients

* Patients with active autoimmune disease of history of autoimmune disease that might recur

* Patients with a history of interstitial lung disease/pneumonitis that required steroids, or current interstitial lung disease/pneumonitis

Other inclusion/exclusion criteria may apply

Dates on the record

Started 22 May 2024
Estimated completion 1 April 2031
Registry last updated 3 September 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 3 September 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.